UBS has started coverage of seeds-and-genetics company Vylor with a buy rating and an $89 price target, arguing that the company's trait-licensing business could deliver profit growth faster than the market currently expects. The bank's analysts see a 10-year licensing runway ahead, driven by Vylor's heavy reinvestment into research and development.
What Vylor does
Vylor sells seeds to farmers, but the higher-margin part of its business is licensing traits—the genetic features that help crops resist pests or tolerate herbicides—to other seed makers. This licensing model allows Vylor to earn steady revenue without the costs of manufacturing and distributing physical seeds, making it a key driver of profitability.
The company reinvests roughly 10% of its sales into R&D, a figure that stands out in the agricultural sector. That spending fuels the development of new traits, which in turn can command premium licensing fees. UBS believes this reinvestment cycle is underappreciated by investors, who may be focusing too much on the slower-growing seed sales side of the business.
The bull case from UBS
UBS's core argument is that Vylor's licensing revenue can grow faster than the market is pricing in. The bank points to steady gains from better crop yields and modest price increases as traits become more valuable to seed makers. Over the next decade, the bank sees a long runway for licensing growth, which could push EBITDA—earnings before interest, taxes, depreciation, and amortization—higher than current consensus estimates through 2029.
This is not the first time an analyst has flagged Vylor's licensing potential. RBC has previously estimated that Vylor's licensing push could hit $1 billion by 2035, underscoring the growing interest in this revenue stream.
Why it matters for investors
For everyday investors, the key takeaway is that Vylor's profit engine may be shifting from selling physical seeds to licensing the genetic traits embedded in them. Licensing is a high-margin, recurring revenue model, similar to how software companies license their products. If UBS is right, Vylor could see profit growth that outpaces its top-line sales growth, which is often a sign of improving business quality.
However, it's worth noting that the $89 price target implies a significant upside from current levels, and the stock may already reflect some of this optimism. Investors should also consider the risks: agricultural markets are cyclical, and trait licensing depends on continued regulatory approval and farmer adoption. A slowdown in either could hit the licensing runway.
Broader market context
The initiation comes at a time when investors are increasingly looking for companies with durable growth stories. Big investors have been trimming AI-heavy US stocks but aren't fleeing the trade entirely, suggesting a search for diversification. Agricultural genetics is a niche but steady corner of the market, and Vylor's R&D-driven model could appeal to those seeking growth outside the tech sector.
Meanwhile, oil stockpiles are 'scarily thin', adding to broader market uncertainty. In such an environment, a company with a clear 10-year growth runway and a defensive agricultural base might be seen as a relative safe haven.
What to watch next
Investors will likely focus on Vylor's upcoming earnings reports to see if licensing revenue is indeed accelerating. Key metrics to watch include the number of new trait licensing deals, the pace of R&D spending, and any updates to the company's long-term guidance. UBS's $89 price target is a strong endorsement, but the market will need to see tangible progress to justify the valuation.
As with any stock, it's important to do your own research and consider how Vylor fits into your overall portfolio. Analyst ratings are just one piece of the puzzle, and the agricultural sector has its own unique risks, from weather to commodity prices.
